Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Severe Influenza Infection

NCT04298060 is registered in ClinicalTrials.gov with Ansun Biopharma, Inc. as lead sponsor.

NCT NCT04298060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04298060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Severe Influenza Infection
Lead sponsor
Ansun Biopharma, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
July 31, 2020
Completion date
September 30, 2022
Enrollment
280 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza infection, sad-rv infection and covid-19